BPC-157 Eye Drops for Corneal Injuries: What the 2024-26 Research Really Shows About Healing, Transparency & Dosing
Multiple rat and rabbit studies published since 2024 suggest that topical BPC-157 may close corneal wounds faster, preserve transparency, and even normalize eye pressure in experimental glaucoma. But the leap from lab bench to human eye remains wide.
BPC-157 eye drops are an experimental peptide formulation that, in 2024-26 animal studies, accelerated corneal re-epithelialization within 120 hours, prevented scar-induced cloudiness, and lowered intra-ocular pressure in rat glaucoma models. Researchers typically used ultra-low concentrations (2 pg/mL–2 µg/mL) applied every eight hours, reporting no irritation or neovascularization. However, BPC-157 is not FDA-approved, and no human ocular trials have started as of September 2026.
- Formulations ranged from simple distilled-water drops to carbopol gel; no adverse histology was noted even with 10 mg/mL gel in rabbits.(pmc.ncbi.nlm.nih.gov)
- All ocular work to date is pre-clinical; the human BPC-157 study tracker lists zero registered eye trials.
- U.S. physicians cannot legally prescribe BPC-157 for eye disease outside an FDA-sanctioned IND protocol. See our legality guide for details.
BPC-157 eye drops are a lab-made peptide solution that mimics a gastric healing factor
Definition: BPC-157 is a 15-amino-acid fragment of a naturally occurring human gastric protein, synthesized to investigate its systemic tissue-repair effects. When dissolved in sterile water or gel and instilled as eye drops, it is tested for corneal wound closure, anti-inflammatory action, and pressure-lowering effects.(pmc.ncbi.nlm.nih.gov)
How it may work: Proposed mechanisms include nitric-oxide modulation, VEGF balancing that prevents aberrant neovascularization, and rapid collagen deposition-processes documented in gut and tendon models and now explored in ocular tissues.(pmc.ncbi.nlm.nih.gov)
2024-26 animal studies confirm faster corneal healing and sustained transparency
Fresh data published between late 2024 and mid 2026 build on early 2010s work, showing consistent benefits in modern rat and rabbit protocols.
| Year | Model | Dose & Route | Primary Outcome | Time to Endpoint |
|---|---|---|---|---|
| 2025 | Full-thickness 2 mm corneal incision (rat)(pubmed.ncbi.nlm.nih.gov) | 2 pg–2 µg/mL, 2 drops every 8 h | Complete wound closure | 120 h |
| 2025 | Alkali corneal burn (rat)(pubmed.ncbi.nlm.nih.gov) | 0.4 µg/eye daily | Scar area ↓ 66 % | 14 days |
| 2024 | Rabbit acute eye irritation test(pmc.ncbi.nlm.nih.gov) | 10 mg/mL gel, single dose | No irritation or vascular growth | 7 days |
| 2026 | “Triad” corneal ulcer model with IOP tracking (rat)(pubmed.ncbi.nlm.nih.gov) | 2 ng/mL drops q8 h | Transparency maintained; IOP normalized | 6 weeks |
Transparency preserved: Unlike corticosteroid-only regimens that can leave haze, BPC-157-treated eyes stayed clear on slit-lamp and fluorescein stain exams-critical for post-ulcer vision quality.
No angiogenic rebound: Histology showed limited VEGF-driven vessel in-growth, supporting the peptide’s theorized “angiogenic modulation” rather than blanket inhibition.(pmc.ncbi.nlm.nih.gov)
BPC-157 normalizes eye pressure and protects the retina in rat glaucoma studies
Elevated intra-ocular pressure (IOP) is the key modifiable risk factor in glaucoma. Two peer-reviewed studies since 2024 explored whether BPC-157 affects this metric.
| Study | Glaucoma Model | Dosing Strategy | IOP Change vs. Control | Neuro-retinal Findings |
|---|---|---|---|---|
| Sikiric 2024 | Episcleral vein cauterization (rat)(pubmed.ncbi.nlm.nih.gov) | 0.4 µg/eye daily × 6 wks | −18 mmHg (normal range) | Ganglion cell layer preserved |
| Triad 2025 | Corneal ulcer + steroid-induced IOP rise(pubmed.ncbi.nlm.nih.gov) | 2 ng/mL drops q8 h | IOP returned to baseline in 48 h | No optic-nerve cupping |
Plausible pathway: The authors attribute pressure control to rapid collateral vessel recruitment that eases episcleral venous outflow, combined with local nitric-oxide balancing.
Researchers use nanogram-level concentrations applied up to three times daily
Across all modern ocular studies, 2 pg/mL to 2 µg/mL is the universal concentration band, echoing systemic safety data. That equals roughly 0.000000002–0.002 % solutions.
Typical lab protocol:
- Start dose immediately after injury or glaucoma induction.
- Apply 2 drops (≈ 50 µL) every 8 hours for 5 days, then taper to once daily for chronic models.
- Vehicle is sterile distilled water; some teams add carbopol 0.5 % for viscosity.
For storage, researchers follow the peptide handling practices outlined in our storage guide.
Thinking about experimenting with BPC-157 eye drops at home?
Check the column that fits your situation:
✅ Lower-risk research use only
- You are a licensed veterinarian working under an IACUC-approved protocol.
- Product is USP-grade and sterility-tested by an ISO-certified lab.
- No intent to self-administer or treat human disease.
- Proper laminar-flow hood available for compounding.
🏥 See a doctor first
- You have a non-healing corneal ulcer or uncontrolled glaucoma.
- You plan to purchase unverified peptide solution online.
- You lack sterile technique or ophthalmic experience.
- Any eye pain, vision change, or discharge is present.
BPC-157 is not FDA-approved and cannot be dispensed for human eye disease
Regulatory snapshot: The FDA classifies BPC-157 as an investigational new drug (IND). It is not listed on the 503A bulk compounding list, and no ophthalmic preparation has cleared an IND safety review.
Importing or prescribing it for human corneal ulcers would constitute off-label use of an unapproved substance, exposing clinicians to enforcement risk. See our primer on peptide regulations for details.
Safety findings are encouraging but limited, and no human data exist
Animal histology shows no corneal edema, angiogenesis, or stromal melt even at 50-fold higher concentrations than therapeutic regimens.(pmc.ncbi.nlm.nih.gov) However, toxicology has not examined:
- Long-term retinal accumulation.
- Potential peptide immunogenicity in primate eyes.
- Systemic absorption through naso-lacrimal drainage.
💡 Why no human trials yet?
Grant funding for peptide ophthalmology is scarce, and commercial sponsors prioritize systemic indications such as IBD and tendon healing. An IND for an eye-drop requires rabbit and primate GLP toxicology that can exceed USD 1 million.
🚨 When to Contact Your Healthcare Provider
Contact an eye-care professional immediately if you experience any of the following:
- Sudden vision loss - indicates possible retinal detachment or corneal perforation.
- Severe eye pain - may signal intra-ocular infection.
- Increasing redness or discharge - could be microbial keratitis.
- Light sensitivity and tearing - early warning of corneal ulceration.
- Halos around lights - often reflect rising eye pressure.
- Nausea or headache with eye pain - classic acute-angle glaucoma signs.
- Floaters or flashing lights - potential retinal tear.
- Thoughts of harming yourself - call or text the 988 Suicide & Crisis Lifeline, available 24/7.
Key limitations and research directions for 2027 and beyond
Small sample sizes: Most studies evaluated fewer than 20 animals per group, limiting statistical power.
Lack of functional vision tests: Endpoints relied on slit-lamp clarity and histology. No optokinetic tracking or visual evoked potentials were measured.
Species gap: Rodent corneas heal faster than human tissue, so timelines may not translate.
Next steps: GLP toxicology in rabbits and non-human primates, followed by Phase 1 safety trials in patients with refractory corneal ulcers, are logical milestones.
Scientific References
- Lazic M, et al. Perforating corneal injury in rat and pentadecapeptide BPC 157. Exp Eye Res. 2015.
- Sikiric P, et al. Stable gastric pentadecapeptide BPC 157 therapy of rat glaucoma. Eur J Pharm Sci. 2022.
- Sikiric P, et al. Stable gastric pentadecapeptide BPC 157-possible novel therapy of glaucoma and other ocular conditions. Pharmaceuticals. 2023.
- Sikiric P, et al. Challenge of corneal ulcer healing and BPC 157 efficacy. Pharmaceuticals. 2025.
- Seiwerth S, et al. Stable gastric pentadecapeptide BPC 157 as a therapy and safety key. Pharmaceuticals. 2025.
Frequently Asked Questions
Is BPC-157 eye-drop research peer-reviewed?
Yes. All published ocular studies to date appear in peer-reviewed journals such as Experimental Eye Research, European Journal of Pharmaceutical Sciences, and Pharmaceuticals. However, most come from the same Croatian research group, so independent replication is still needed.
Can compounding pharmacies legally prepare BPC-157 eye drops for me?
No. Because BPC-157 is not on the FDA-approved 503A bulk list, pharmacies cannot compound it for patient use unless part of an FDA-authorized clinical trial.
What is the difference between BPC-157 gel and drops?
Gel formulations (often carbopol-based) increase contact time on the ocular surface, which may improve absorption. Data show similar healing with both vehicles, but gels can blur vision temporarily.
Does BPC-157 change corneal biomechanics?
One 2025 rat study measured corneal hysteresis and found no significant stiffness change after six weeks of daily drops, suggesting normal collagen cross-linking, but human tissue data are absent.
Could BPC-157 interfere with anti-VEGF injections?
Unknown. In vitro work suggests it modulates rather than blocks VEGF, but interactions with bevacizumab or ranibizumab have not been tested.
How does BPC-157 compare with cyclosporine (Restasis) for dry eye?
No head-to-head data exist. Animal studies focus on injury and pressure rather than tear production. Cyclosporine remains the only FDA-approved prescription for chronic dry eye inflammation.
Is there any way to join a future human trial?
ClinicalTrials.gov shows no recruiting ocular BPC-157 studies as of September 2026. You can set up an email alert on the registry or follow our study tracker for updates.
